Literature DB >> 22215138

Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding.

Leticia Huergo-Zapico1, Ana P Gonzalez-Rodriguez, Juan Contesti, Esther Gonzalez, Alejandro López-Soto, Azahara Fernandez-Guizan, Andrea Acebes-Huerta, Juan R de Los Toyos, Carlos Lopez-Larrea, Veronika Groh, Thomas Spies, Segundo Gonzalez.   

Abstract

MICA is a ligand of the activating receptor NKG2D, expressed by NK and T cells. MICA expression is induced in cancer cells favoring their elimination by the immune system; however, many advanced tumors shed soluble MICA (sMICA), which impairs NKG2D-mediated cytotoxicity. ERp5 and GRP78 are endoplasmic reticulum-resident proteins that are translocated to the surface of epithelial tumor cells where they interact with MICA and are involved in sMICA shedding. In this study, we analyze the role of ERp5 and GRP78 in sMICA shedding in chronic lymphocytic leukemia (CLL). Immunofluorescence and flow cytometry analyses showed that ERp5 and GRP78 were significantly expressed on the surface of B cells and leukemia cells, but they were not expressed on T cells. The expression of ERp5 and GRP78 was significantly higher in leukemia cells than in B cells from controls. ERp5 and GRP78 co-localized with MICA on the surface of leukemia cells and the levels of expression of ERp5 and GRP78 correlated with the level of expression of membrane-bound MICA in CLL patients. Associated with higher expression of membrane-bound ERp5 and GRP78, serum sMICA levels were approximately threefold higher in patients than in controls. Elevated sMICA levels in CLL patients were associated with the down-modulation of NKG2D surface expression on CD8 T cells. Finally, pharmacological inhibition of B cell lines and stimulated leukemia cells showed that ERp5 activity is involved in sMICA shedding in CLL. In conclusion, these results uncover a molecular mechanism which regulates MICA protein shedding and immune evasion in CLL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22215138     DOI: 10.1007/s00262-011-1195-z

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  19 in total

1.  Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia.

Authors:  A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez
Journal:  Genes Immun       Date:  2014-11-13       Impact factor: 2.676

2.  Therapeutic targeting of membrane-associated GRP78 in leukemia and lymphoma: preclinical efficacy in vitro and formal toxicity study of BMTP-78 in rodents and primates.

Authors:  D I Staquicini; S D'Angelo; F Ferrara; K Karjalainen; G Sharma; T L Smith; C A Tarleton; D E Jaalouk; A Kuniyasu; W B Baze; B K Chaffee; P W Hanley; K F Barnhart; E Koivunen; S Marchiò; R L Sidman; J E Cortes; H M Kantarjian; W Arap; R Pasqualini
Journal:  Pharmacogenomics J       Date:  2017-12-05       Impact factor: 3.550

Review 3.  Role of NKG2D and its ligands in cancer immunotherapy.

Authors:  Huifang Liu; Sijia Wang; Jing Xin; Jing Wang; Cuiping Yao; Zhenxi Zhang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

4.  Quantification of anti-sperm antibody and soluble MICA/MICB levels in the serum of infertile people of the Li ethnic group in China.

Authors:  Xiaobin Wei; Zhouxin Han; Biqiong Ren; Xi Xiao; Feng Li; Danqin Lin; Bin Luo; Xianxian Fu; Chunyun Li; Huan Xia; Ping Yu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 5.  Immunobiology and conflicting roles of the human NKG2D lymphocyte receptor and its ligands in cancer.

Authors:  Ahmed El-Gazzar; Veronika Groh; Thomas Spies
Journal:  J Immunol       Date:  2013-08-15       Impact factor: 5.422

6.  Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.

Authors:  Katrin S Reiners; Daniela Topolar; Alexander Henke; Venkateswara R Simhadri; Jörg Kessler; Maike Sauer; Martina Bessler; Hinrich P Hansen; Samir Tawadros; Marco Herling; Martin Krönke; Michael Hallek; Elke Pogge von Strandmann
Journal:  Blood       Date:  2013-03-18       Impact factor: 22.113

Review 7.  Molecular Bases for the Regulation of NKG2D Ligands in Cancer.

Authors:  Leticia Huergo-Zapico; Andrea Acebes-Huerta; Alejandro López-Soto; Mónica Villa-Álvarez; Ana Pilar Gonzalez-Rodriguez; Segundo Gonzalez
Journal:  Front Immunol       Date:  2014-03-21       Impact factor: 7.561

8.  Combination immune therapies to enhance anti-tumor responses by NK cells.

Authors:  Ashley Mentlik James; Adam D Cohen; Kerry S Campbell
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

Review 9.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923

Review 10.  How to exploit stress-related immunity against Hodgkin's lymphoma: Targeting ERp5 and ADAM sheddases.

Authors:  Alessandro Poggi; Maria Raffaella Zocchi
Journal:  Oncoimmunology       Date:  2013-12-05       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.